Ortho Clinical Diagnostics Holdings plc

Ortho Clinical Diagnostics Holdings plc

OCDX

OCDXOrtho Clinical Diagnostics Holdings plc US flag

NASDAQ Global Select

17.63

USD

+0.16

- -

Ortho Clinical Diagnostics Holdings plc

OCDX

(NASDAQ Global Select)

Recent

price

17.63

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: DermTech, Inc. (DMTK)
Mega Genomics Limited (6667.HK)
Izotropic Corporation (IZOZF)
Sotera Health Company (SHC)
PT Prodia Widyahusada Tbk (PRDA.JK)
Genomic Vision S.A. (GV.PA)
Business: Ortho Clinical Diagnostics Holdings plc is a global in vitro diagnostics company that develops, manufactures, and markets a comprehensive portfolio of diagnostic products primarily for transfusion medicine, clinical chemistry, immunoassay, and blood donor screening. Its main products and services include immunohematology testing systems such as the ORTHO VISION™ Analyzer and the ORTHO® Workstation; clinical chemistry and immunoassay platforms including the VITROS® 250/350 and VITROS 5600 Systems; rapid lateral-flow diagnostic tests like QUICKVUE®; molecular diagnostics assays such as the LYRA® real-time PCR assays; and point-of-care diagnostic solutions with the QUIDEL™ TRIAGE™ System. The company serves laboratories, hospitals, blood banks, and healthcare providers worldwide, operating in more than 130 countries. Founded in 1939, Ortho Clinical Diagnostics is headquartered in Raritan, New Jersey. A major corporate development was the 2022 completion of its merger with Quidel Corporation, creating QuidelOrtho Corporation, a global diagnostics leader with an enhanced product portfolio spanning high-throughput systems, point-of-care testing, molecular diagnostics, and immunohematology. This transaction expanded Ortho's geographic reach, combined complementary technologies, and aimed to accelerate growth through enhanced R&D capabilities and cross-selling opportunities. The merged entity continues to develop and commercialize innovative diagnostic solutions, strengthening its presence across clinical reference labs, hospitals, physician offices, urgent care centers, and at-home testing markets. Recent strategic initiatives include plans to acquire full ownership of LEX Diagnostics following FDA clearance to support growth in molecular diagnostics. Ortho Clinical Diagnostics operates within the medical diagnostics industry with segments covering transfusion medicine, immunoassay and clinical chemistry platforms, molecular diagnostics, and rapid diagnostic testing. Its products address patient testing needs throughout the healthcare continuum, emphasizing enhanced lab workflow efficiencies, data security, and reliable diagnostic accuracy. The company is a wholly owned subsidiary of QuidelOrtho and remains headquartered in New Jersey while leveraging a global footprint for sales and support. The merger with Quidel marked a strategic shift toward a more diversified and balanced product portfolio aimed at long-term shareholder value creation and global market expansion.

Company News